Literature DB >> 27539605

SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

Ian H de Boer1,2, Steven E Kahn2,3.   

Abstract

Entities:  

Keywords:  chronic kidney disease; clinical trial; diabetes mellitus; diabetic nephropathy

Mesh：

Substances：

Year:  2016        PMID： 27539605      PMCID： PMC5198295          DOI： 10.1681/ASN.2016060650

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  15 in total

Review 1.  7. Approaches to Glycemic Treatment.

Authors: 
Journal:  Diabetes Care       Date:  2016-01       Impact factor: 19.112

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

4.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

5.  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.

Authors:  Hiddo J L Heerspink; Mehul Desai; Meg Jardine; Dainius Balis; Gary Meininger; Vlado Perkovic
Journal:  J Am Soc Nephrol       Date:  2016-08-18       Impact factor: 10.121

Review 6.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Authors:  Steven E Kahn; Mark E Cooper; Stefano Del Prato
Journal:  Lancet       Date:  2013-12-03       Impact factor: 79.321

7.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Jennifer B Green; M Angelyn Bethel; Paul W Armstrong; John B Buse; Samuel S Engel; Jyotsna Garg; Robert Josse; Keith D Kaufman; Joerg Koglin; Scott Korn; John M Lachin; Darren K McGuire; Michael J Pencina; Eberhard Standl; Peter P Stein; Shailaja Suryawanshi; Frans Van de Werf; Eric D Peterson; Rury R Holman
Journal:  N Engl J Med       Date:  2015-06-08       Impact factor: 91.245

8.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

9.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
View more
  4 in total

Review 1.  Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD.

Authors:  Alexander J Kula
Journal:  Pediatr Nephrol       Date:  2022-01-27       Impact factor: 3.651

Review 2.  Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.

Authors:  Manfred Hecking; Adnan Sharif; Kathrin Eller; Trond Jenssen
Journal:  Transpl Int       Date:  2020-11-28       Impact factor: 3.782

Review 3.  SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.

Authors:  Honghong Zou; Baoqin Zhou; Gaosi Xu
Journal:  Cardiovasc Diabetol       Date:  2017-05-16       Impact factor: 9.951

4.  Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.

Authors:  Xingxing An; Guangneng Liao; Younan Chen; Ai Luo; Jingping Liu; Yujia Yuan; Lan Li; Lichuan Yang; Hong Wang; Fang Liu; Guang Yang; Shounan Yi; Yuanmin Li; Jingqiu Cheng; Yanrong Lu
Journal:  Stem Cell Res Ther       Date:  2019-12-02       Impact factor: 6.832
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.